Physician's Weekly2d
Immune Checkpoint Inhibitors and Survival Trends in MCC
The following is a summary of “Improved survival at the population level for patients with advanced Merkel cell carcinoma ...
Merkel Cell Carcinoma Market is Expected to Advance at a CAGR of 8.7% During the Study Period (2020-2034) | DelveInsight
The Merkel Cell Carcinoma Market is expected to grow significantly in the 7MM, driven by the rising awareness among ...
Merkel Cell Carcinoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
The leading Merkel Cell Carcinoma Companies such as ImmunityBio, OncoSec Medical, Exelixis, 4SC, Kartos Therapeutics, Incyte ...
BioWorld7d
AURKB unveiled as a druggable target in Merkel cell carcinoma
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer with a high mortality rate and characterized by ...
Managed Healthcare Executive3d
Melanoma Treatment Advances Now Crossing into Other Skin Cancers
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
BAVENCIO Continues to Strengthen Its Position in the Immuno-Oncology Landscape | DelveInsight
DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...
The Daily of the University of Washington13d
The Merkel Cell Carcinoma Collaborative Institute launches, igniting a new era of research into a rare skin cancer
UW Medicine launched the Merkel Cell Carcinoma Collaborative (MC3) Institute on Jan. 27 to cure an aggressive form of skin ...
American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts--(Newsfile ...
TuHURA Biosciences, Inc. to Present at the 37th Annual ROTH Conference
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two ...